High-Level Immunogenicity Is Achieved Vaccine With Adjuvanted Pandemic H1N1₂₀₀₉ and Improved With Booster Dosing in a Randomized Trial of HIV-Infected Adults

REFERENCES

• Beck JM, Rosen MJ, Peavy HH. Pulmonary complications of HIV infection. Report of the Fourth NHLBI Workshop. Am J Respir Crit Care Med. 2001164: 2120–2126.
   Google Scholar
• Malaspina A, Moir S, Orsega SM, et al. Compromised B cell responses to influenza vaccination in HIV-infected individuals. J Infect Dis. 2005;191:1442–1450.
   PubMed Web of Science ®Google Scholar
• Zanetti AR, Amendola A, Besana S, Boschini A, Tanzi E. Safety and immunogenicity of influenza vaccination in individuals infected with HIV. Vaccine. 2002;20(Suppl 5):629–32.
   Google Scholar
• Beck JM, Rosen MJ, Peavy HH. Pulmonary complications of HIV infection. 4th NHLBI Workshop. Vol. 164. Am J Respir Crit Care Med. 2001:2120–2126.
   Web of Science ®Google Scholar
• Fine AD, Bridges CB, De Guzman AM, et al. Influenza A among patients with human immunodeficiency virus: an out-break of infection at a residential facility in New York City. Clin Infect Dis. 2001;32:1784–1791.
   PubMed Web of Science ®Google Scholar
• Radwan HM, Cheeseman SH, Lai KK, Ellison IR. Influenza in human immunodeficiency virus-infected patients during the 1997-1998 influenza season. Clin Infect Dis. 2000;31:604–606.
   PubMed Web of Science ®Google Scholar
• Safrin S, Rush JD, Mills J. Influenza in patients with human immunodeficiency virus infection. Chest. 1990;98:33–37.
   PubMed Web of Science ®Google Scholar
• Lin JC, Nichol KL. Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch Intern Med. 2001161: 441–446.
   Google Scholar
• Ragni MV, Ruben FL, Winkelstein A, Spero JA, Bontempo FA, Lewis JH. Antibody responses to immunization of patients with hemophilia with and without evidence of human immuno-deficiency virus (human T-Iymphotropic virus type III) infection. J Lab Clin Med. 1987;109:545–549.
   PubMed Web of Science ®Google Scholar
• Redfield RR, Wright DC, James WD, Jones TS, Brown C, Burke DS. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N Engl J Med. 1987;316:673–676.
   PubMed Web of Science ®Google Scholar
• Kroon FP, van Dissel JT, de Jong JC, Zwinderman K, van Furth R. Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study. Vac-cine. 2000;18:3040–3049.
   PubMed Web of Science ®Google Scholar
• Staprans SI, Hamilton BL, Follansbee SE, et al. Activation of virus replication after vaccination of HIV-1-infected indi-viduals. J Exp Med. 1995;182:1727–1737.
   PubMed Web of Science ®Google Scholar
• Evison J, Farese S, Seitz M, Uehlinger DE, Furrer H, Muhlemann K. Randomized, double-blind comparative trial of subunit and virosomal influenza vaccines for immu-nocompromised patients. Clin Infect Dis. 2009;48:1402–1412.
   PubMed Web of Science ®Google Scholar
• Klein MB, Lu Y, DelBalso L, Cote S, Boivin G. Influenzavi-rus infection is a primary cause of febrile respiratory illness in HIV-infected adults, despite vaccination. Clin Infect Dis. 2007;45:234–240.
   PubMed Web of Science ®Google Scholar
• Bickel M, von Hentig N, Wieters I, et al. Immune response after two doses of the novel split virion, adjuvanted pan-demic Hi Ni influenza A vaccine in HIV-1-infected patients. Clin Infect Dis. 201152: 122–127.
   Google Scholar
• Crum-Cianflone NF, Eberly LE, Duplessis C, et al. Immuno-genicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults. Clin Infect Dis. 2011;52:138–146.
   PubMed Web of Science ®Google Scholar
• Ho J, Moir S, Wang W, et al. Enhancing effects of adju-vanted 2009 pandemic Hi Ni influenza A vaccine on memory B-cell responses in HIV-infected individuals. AIDS. 2011 25: 295–302.
   PubMed Web of Science ®Google Scholar
• Kajaste-Rudnitski A, Galli L, Nozza S, et al. Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals. AIDS. 2011;25:177–183.
   PubMed Web of Science ®Google Scholar
• Manuel O, Pascual M, Hoschler K, et al. Humoral response to the influenza A H1N1/09 monovalent A503-adjuvanted vaccine in immunocompromised patients. Clin Infect Dis. 2011;52:248–256.
   PubMed Web of Science ®Google Scholar
• Orlando G, Pariani E, Mazza F, et al. Pandemic influ-enza vaccine in adult HIV-1-infected patients. AIDS. 2010;24:2142–2143.
   PubMed Web of Science ®Google Scholar
• Soonawala D, Rimmelzwaan GF, Gelinck LB, Visser LG, Kroon FP. Response to 2009 pandemic influenza A (Hi Ni) vaccine in HIV-infected patients and the influence of prior seasonal influenza vaccination. PLoS One. 2011;6:e16496
   PubMed Web of Science ®Google Scholar
• Rowe T, Abernathy RA, Hu-Primmer J, et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Micro-bioL 1999;37:937–943.
   PubMed Web of Science ®Google Scholar
• Committee for Proprietary Medicinal Products. Note for Guidance on Harmonisation of Requirements for Influenza Vaccines. In: The European Agency for the Evaluation of Medicinal Products - Human Medicines Evaluation Unit, ed. Committee for Proprietary Medicinal Products/Biotechnology Working Party/214/96. London, UK: The European Agency for the Evaluation of Medicinal Products; 1997.
   Google Scholar
• Cooper C, Thorne A, Klein M, et al. Immunogenicity is not improved by increased antigen dose or booster dosing of seasonal influenza vaccine in a randomized trial of HIV infected adults. PLoS One. 2011;6:e17758.
   PubMed Web of Science ®Google Scholar
• Powers DC, Smith GE, Anderson EL, et al. Influenza A virus vaccines containing purified recombinant H3 hemag-glutinin are well tolerated and induce protective immune responses in healthy adults. J Infect Dis. 1995;171:1595–1599.
   PubMed Web of Science ®Google Scholar
• Skea DL, Barber BH. Adhesion-mediated enhancement of the adjuvant activity of alum. Vaccine. 1993;11:1018–1026.
   PubMed Web of Science ®Google Scholar
• Cooper CL, Angel JB, Seguin I, Davis HL, Cameron DW. CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years. Clin Infect Dis. 2008;46:1310–1314.
   PubMed Web of Science ®Google Scholar
• Cooper CL, Davis H, Cameron DW. Influenza vaccination with 1/10th the full dose. N Engl J Med. 2004;351:2339–2340.
   PubMed Web of Science ®Google Scholar
• Cooper CL, Davis HL, Morris ML, et al. Safety and immu-nogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine. 2004;22:3136–3143.
   PubMed Web of Science ®Google Scholar
• Castellino F, Galli G, Del Giudice G, Rappuoli R. Generating memory with vaccination. Eur J Immunol. 2009;39:210–2105.
   Web of Science ®Google Scholar
• Bares B, Stittelaar KJ, Simon JH, et al. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS One. 2008;3:e1401.
   PubMed Web of Science ®Google Scholar
• Leroux-Roels I, Borkowski A, Vanwolleghem T, et al. Antigen sparing and cross-reactive immunity with an adju-vanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet. 2007;370:580–589.
   PubMed Web of Science ®Google Scholar
• Banzhoff A, Nacci P, Podda A. A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunoge-nicity meta-analysis. Gerontology. 2003;49:177–184.
   PubMed Web of Science ®Google Scholar
• Durando P, Fenoglio D, Boschini A, et al. Safety and immu-nogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immu-nodeficiency virus type 1-seropositive and -seronegative adults. Clin Vaccine Immunol. 2008;15:253–259.
   PubMed Web of Science ®Google Scholar
• Huang KL, Ruben FL, Rinaldo CR Jr, Kingsley L, Lyter DW, Ho M. Antibody responses after influenza and pneu-mococcal immunization in HIV-infected homosexual men. JAMA. 1987;257:2047–2050.
   PubMed Web of Science ®Google Scholar
• Tremblay CL, Rouleau D, Fortin C, et al. Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients. Vac-cine. 2011;29:1359–1363.
   PubMed Web of Science ®Google Scholar
• Fabbiani M, Di Giambenedetto S, Sali M, et al. Immune response to influenza A (H1 N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients. Vaccine. 2011;29:2836–2839.
   PubMed Web of Science ®Google Scholar
• Smith NM, Bresee JS, Shay DK, Uyeki TM, Cox NJ, Strikas RA. Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006;55:1–42.
   PubMedGoogle Scholar
• Nichol KL. Booster doses of influenza vaccine. JAMA. 1996;276:1857.
   PubMed Web of Science ®Google Scholar
• Lorio AM, Alatri A, Francisci D, et al. Immunogenicity of influenza vaccine (1993-94 winter season) in HIV-seroposi-tive and -seronegative ex-intravenous drug users. Vaccine. 1997;15:97–102.
   PubMed Web of Science ®Google Scholar
• Miotti PG, Nelson KE, Dallabetta GA, Farzadegan H, Mar-golick J, Clements ML. The influence of HIV infection on antibody responses to a two-dose regimen of influenza vaccine. JAMA. 1989;262:779–783.
   PubMed Web of Science ®Google Scholar
• Anema A, Mills E, Montaner J, Brownstein JS, Coo-per C. Efficacy of influenza vaccination in HIV-positive patients: a systematic review and meta-analysis. HIV Med. 2008;9:57–61.
   PubMed Web of Science ®Google Scholar
• Cooper C, Thorne A, Walmsley S, et al. A controlled trial to compare the immunogenicity and efficacy of 3 seasonal influenza vaccine dosing strategies in HIV-infected adults. Presented at: Conference on Retro-viruses and Opportunistic Infections (CR01); 2010; San Francisco, CA.
   Google Scholar
• Launay O, Desaint C, Durier C, et al. Safety and immu-nogenicity of a monovalent 2009 influenza A/H1N1v vac-cine adjuvanted with ASO3A or unadjuvanted in HIV-infected adults: a randomized, controlled trial. J Infect Dis. 2011204: 124–134.
   Google Scholar
• Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without ASO3A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine. 2010;28:1740–1745.
   PubMed Web of Science ®Google Scholar
• Roman F, Vaman T, Kafeja F, Hanon E, Van Damme P. A503(A)-Adjuvanted influenza A (Hi Ni) 2009 vaccine for adults up to 85 years of age. Clin Infect Dis. 2010;51:668–677.
   PubMed Web of Science ®Google Scholar
• Hancock K, Veguilla V, Lu X, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med. 2009;361:1945–1952.
   PubMed Web of Science ®Google Scholar
• Skowronski DM, Hottes TS, Janjua NZ, et al. Prevalence of seroprotection against the pandemic (Hi Ni) virus after the 2009 pandemic. Can Med Assoc J. 2010;182:1851–1856.
   Web of Science ®Google Scholar
• Greenberg ME, Lai MH, Hertel GF, et al. Response to a monovalent 2009 influenza A (Hi Ni) vaccine. N Engl J Med. 2009;361:2405–2413.
   PubMed Web of Science ®Google Scholar
• Zhu FC, Wang H, Fang HH, et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med. 2009;361:2414–2423.
   PubMed Web of Science ®Google Scholar
• Geretti AM, Brook G, Cameron C, et al. British HIV Asso-ciation guidelines for immunization of HIV-infected adults 2008. HIV Med. 2008;9:795–848.
   PubMed Web of Science ®Google Scholar
• Statement on Seasonal Trivalent Inactivated Influenza Vac-cine (TIV) for 2010–2011. Canada Communicable Disease Report. Volume 36; Advisory Committee Statement 6; August 2010. Ottawa: Public Health Agency of Canada; 2010.
   Google Scholar
• Karlsson EA, Sheridan PA, Beck MA. Diet-induced obesity impairs the T cell memory response to influenza virus infection. J Immunol. 2010;184:3127–3133.
   PubMed Web of Science ®Google Scholar